<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE
COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
ICU Medical, Inc.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
-------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------------
Notes:
<PAGE>
ICU MEDICAL, INC.
951 CALLE AMANECER
SAN CLEMENTE, CALIFORNIA 92673
______________________
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 5, 2000
______________________
This Annual meeting of Stockholders of ICU Medical, Inc. (the "Company") will be
held at the San Clemente Inn, 2600 Avenida Del Presidente, San Clemente,
California, Friday, May 5, 2000 at 10:00 a.m., Pacific Daylight Time, for the
following purposes:
1. To elect two directors of the Company to serve for a term of three
years and until their successors have been elected and qualified;
2. To ratify the selection of Arthur Andersen LLP, independent
certified public accountants, as auditors for the Company for the year
ending December 31, 2000; and
3. To transact such other business as may properly come before the
Annual Meeting or any adjournment thereof.
The Board of Directors has determined that only holders of Common Stock of
record at the close of business on March 6, 2000 will be entitled to receive
notice of, and to vote at, the Annual Meeting or any adjournment thereof.
The Board of Directors
/S/ Francis J. O'Brien
------------------------------
Francis J. O'Brien, Secretary
San Clemente, CA
March 20, 2000
YOUR VOTE IS IMPORTANT
Please complete, sign, date and return the enclosed proxy promptly even
though you plan to attend the meeting in person. If you attend the meeting, you
may withdraw your proxy and vote in person.
THANK YOU FOR ACTING PROMPTLY
<PAGE>
ICU MEDICAL, INC.
951 CALLE AMANECER
SAN CLEMENTE, CALIFORNIA 92673
PROXY STATEMENT
This Proxy Statement is furnished in connection with the solicitation of
proxies by the Board of Directors of ICU Medical, Inc. (the "Company") for use
at the Annual Meeting of Stockholders to be held May 5, 2000, at the San
Clemente Inn, 2600 Avenida Del Presidente, San Clemente, California at 10:00
a.m., Pacific Daylight Time, and at any adjournments thereof, for the purposes
set forth herein and in the accompanying Notice. The approximate date of mailing
of this Proxy Statement and the accompanying proxy is March 20, 2000.
PROXY INFORMATION
A stockholder giving a proxy may revoke it at any time before it is
exercised by filing with the Secretary of the Company a written notice of
revocation or a duly executed proxy bearing a later date. The powers of the
proxy holders will be suspended if the person executing the proxy is present at
the Annual Meeting and elects to vote in person. Subject to such revocation or
suspension, all shares represented by each properly executed proxy received by
the Company will be voted in accordance with the instructions indicated thereon,
and if instructions are not indicated, will be voted in favor of (i) the
election of the nominees for director named in, or otherwise nominated as set
forth in, this Proxy Statement and (ii) the proposal to ratify the selection of
independent certified public accountants.
RECORD DATE AND VOTING
As of March 6, 2000, the outstanding voting securities of the Company
consisted of 8,304,039 shares of $.10 par value Common Stock. Each stockholder
of record at the close of business on March 6, 2000 is entitled to one vote for
each share then held on each matter submitted to a vote of stockholders. The
presence in person or by proxy of holders of a majority of the issued and
outstanding Common Stock will constitute a quorum for the transaction of such
business as shall properly come before the meeting.
Generally, stockholder approval of a matter, other than the election of
directors, requires the affirmative vote of a majority of the shares present in
person or represented by proxy and entitled to vote on the matter. Directors are
elected by a plurality of the votes of the shares present in person or by proxy
and entitled to vote on the election of directors. Shares voted to abstain on a
matter will be treated as entitled to vote on the matter and will thus have the
same effect as "no" votes. Broker non-votes are not counted as entitled to vote
on a matter in determining the number of affirmative votes required for approval
of the matter, but are counted as present for quorum purposes. The term "broker
non-votes" refers to shares held by a broker in street name which are present by
proxy but are not voted on a matter pursuant to rules prohibiting brokers from
voting on non-routine matters without instructions from the beneficial owner of
the shares. The election of directors and ratification of the selection of
independent certified public accountants are generally considered to be routine
matters on which brokers may vote without instructions from beneficial owners.
1
<PAGE>
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information as to shares of Common Stock
owned as of March 6, 2000, by (i) each person who, insofar as the Company has
been able to ascertain, beneficially owned more than five percent of the
outstanding Common Stock, (ii) each director, (iii) each nominee for election as
a director, and (iv) all directors and officers as a group. Unless otherwise
indicated in the footnotes following the table, and subject to community
property laws where applicable, the Company believes that the persons as to whom
the information is given have sole voting and investment power over the shares
listed as beneficially owned. The business address of the George A. Lopez, M.D.
Second Family Limited Partnership, George A. Lopez, M.D. and Diana K. Lopez,
M.D. is 951 Calle Amanecer, San Clemente, California 92673.
<TABLE>
<CAPTION>
SHARES PERCENT
OWNED OF
BENEFICIALLY CLASS(1)
------------ --------
<S> <C> <C>
Wasatch Advisors.............................................. 2,213,679(8) 22.7%
68 South Main Street, Salt Lake City, UT 84101
George A. Lopez, M.D.......................................... 1,682,397(3) 17.2%
George A. Lopez, M.D. Second Family Limited Partnership ...... 791,742(2) 8.1%
Diana K. Lopez, M.D. ......................................... 1,053,748(4) 10.8%
FMR Corporation............................................... 848,400(8) 8.7%
82 Devonshire Street, Boston, MA 02109
Dimensional Fund Advisors Inc................................. 409,800(8) 4.2%
1299 Ocean Avenue, Santa Monica, CA 90401
Scudder Kemper Investments.................................... 492,800(8) 5.1%
345 Park Avenue, New York, NY 10154
Jack W. Brown................................................. 18,000(5) *
John J. Connors............................................... 11,500(5) *
Michael T. Kovalchik III, M.D................................. 21,275(6) *
Richard H. Sherman, M.D....................................... 79,834(5) *
Robert S. Swinney, M.D........................................ 16,275 *
All officers and directors as a group (9 persons)............. 2,030,040(7) 20.8%
</TABLE>
- ------------
* Less than one percent
(1) Based on total shares of Common Stock outstanding plus outstanding options
to acquire Common Stock currently exercisable or exercisable within 60 days
held by the beneficial owner whose percent of outstanding stock is
calculated.
(2) George A. Lopez, M.D. and Diana K. Lopez, M.D., his wife, are the general
partners of the George A. Lopez, M.D. Second Family Limited Partnership
(the "Partnership") and hold a one-percent general partnership interest in
the Partnership. As general partners, they share power to vote and power to
dispose of the 791,742 shares owned by the Partnership and may be deemed to
be beneficial owners of such shares. Trusts for the benefit of the Lopez'
children, the Christopher George Lopez Children's Trust and the Nicholas
George Lopez Children's Trust, own a 99% limited partnership interest in
the Partnership. The Drs. Lopez are not trustees of and have no interest in
their children's Trusts. Except to the extent of their undivided one
percent general partnership interest in the assets of the Partnership, the
Drs. Lopez disclaim any beneficial ownership of the shares owned by the
Partnership.
(3) Includes options to acquire 890,655 shares. Also includes the 791,742
shares owned by the Partnership, as to which shares Dr. Lopez disclaims any
beneficial ownership except to the extent described in Note (2). Does not
include 12,006 shares owned by his wife, as to which Dr. Lopez disclaims
beneficial ownership, and as to which he has no voting and investment
power. Also does not include 250,000 held by Dr. Lopez' wife as Trustee of
the Lopez CRT #1 for the benefit of Dr. Lopez and his wife, as to which
shares Dr. Lopez has no voting or investment power.
2
<PAGE>
(4) Includes 12,006 shares owned by Diana K. Lopez, M.D. and 250,000 shares
held by her as trustee of the Lopez CRT #1 for the benefit of Diana K.
Lopez, M.D. and George A. Lopez, M.D. Also includes 791,742 shares owned by
the Partnership as to which Dr. Lopez disclaims any beneficial ownership
except to the extent described in Note (2).
(5) Includes options to acquire 7,500 shares.
(6) Includes options to acquire 7,500 shares. Includes 1,700 shares held by Dr.
Kovalchik as custodian for his children. Does not include 1,650 shares
beneficially owned by his wife. Dr. Kovalchik disclaims beneficial
ownership of all of the shares held as custodian and the shares
beneficially owned by his wife.
(7) Includes options to acquire 1,027,064 shares.
(8) Information included solely in reliance information included in a Statement
on Schedule 13D on Form 13G filed with the Securities and Exchange
Commission by the indicated holder.
ELECTION OF DIRECTORS
NOMINEES AND DIRECTORS
Two directors, of the six directors currently constituting the Board of
Directors, are to be elected at the Annual Meeting and to hold office until the
year 2003 Annual Meeting and until their successors are elected and qualified.
The Company's Board of Directors is divided into three classes. Each year a
different class of directors is elected at the Annual Meeting to a three-year
term.
In the election of directors, the proxy holders intend to vote for the
election of Jack. W. Brown and Richard H. Sherman, M.D., who are now members of
the Board and whose current term of office is expiring. It is not anticipated
that the nominees will decline or be unable to serve as directors. If, however,
that should occur, the proxy holders will vote the proxies in their discretion
for any nominee designated to fill the vacancy by the present Board of
Directors.
<TABLE>
<CAPTION>
CURRENT
DIRECTOR TERM
NAME AGE SINCE EXPIRES PRINCIPAL OCCUPATION
- ------------------------------------ --- -------- ------- -----------------------------------------------
<S> <C> <C> <C> <C>
George A. Lopez, M.D. .............. 52 1984 2001 Chairman of the Board, President and Chief
Executive Officer of the Company
Jack W. Brown....................... 60 1992 2000 Former Chairman of the Board and President of
Gish Biomedical, Inc., disposable medical
devices
John J. Connors..................... 60 1992 2002 Patent Attorney
Michael T. Kovalchik III, M.D. ..... 54 1989 2002 Physician and Director of the Dialysis Unit,
Charlotte Hungerford Hospital, Torrington,
Connecticut
Richard H. Sherman, M.D. ........... 53 1990 2000 Physician and Director of the Cardiology
Laboratory and Cardiac Rehabilitation for
Milford Hospital, Milford, Delaware
Robert S. Swinney, M.D. ............ 54 1998 2001 Physician and member of the faculty of the Los
Angeles County-University of Southern
California Medical Center
</TABLE>
3
<PAGE>
Dr. Lopez is the founder of the Company and has served as Chairman of the
Board, President and Chief Executive Officer for more than five years. Dr. Lopez
has held various offices and served as a director of the Company since its
founding in 1984 with some interruptions in service.
Messrs. Brown and Connors and Drs. Kovalchik, Sherman and Swinney have been
engaged in their current occupations for more than five years. Mr. Connors
served as Secretary, Treasurer and Chief Financial Officer of the Company from
April 30, 1996 until November 1, 1996 on an interim basis during a search for a
candidate to fill those positions permanently. Mr. Connors previously served as
a director from December 1988 to July 1989. Dr. Swinney previously served as a
director from 1989 to October 1995.
SPECIAL COMMITTEES AND ATTENDANCE AT MEETINGS
The Board of Directors has an Audit Committee, which consists of Messrs.
Brown and Connors and Dr. Kovalchik. The Audit Committee makes recommendations
regarding the selection of independent public accountants, reviews reports from
the Company's independent public accountants and reviews with them the scope and
results of the audit engagement. The Audit Committee met twice in 1999.
The Board of Directors has a Compensation Committee of the Board,
consisting of Mr. Brown and Drs. Kovalchik and Sherman. The Compensation
Committee, as more fully described in the Compensation Committee Report,
approves salary practices for executive personnel, establishes the compensation
of executive officers and authorizes the grant of stock options. The
Compensation Committee met eight times in 1999. In January 2000, the
Compensation Committee was expanded to include Mr. Connors and Dr. Swinney.
During 1999, the Board met 13 times. Each director attended more than 75%
of the total of all meetings of the Board and any committees on which he serves.
EXECUTIVE COMPENSATION
COMPENSATION COMMITTEE REPORT
During 1999, the Compensation Committee (the "Committee") consisted of
three directors who are not employees or former employees of, or consultants to,
the Company. The Committee approves salary practices for executive personnel,
reviews the performance of the Company and the executive officers, sets
performance objectives, establishes the compensation of executive officers,
including the Chief Executive Officer, and authorizes the grant of options under
the 1993 Stock Incentive Plan.
The Company's policy in compensating executive officers is to establish
methods and levels of compensation that will provide strong incentives to
promote the profitability and growth of the Company and reward superior
performance and that are sufficiently competitive to attract, retain and
motivate highly competent management personnel. Compensation of executive
officers includes base salary, performance-based incentive bonuses and
stock-based programs.
The Committee has adopted an executive compensation policy which provides a
base salary and, if certain performance objectives are met, incentive bonuses
and stock options which are awarded and paid semi-annually. The Committee
considers total compensation paid to executive officers holding comparable
positions in comparable companies and for 1999 set base salaries of the
Company's executive officers at or above the middle of the range of comparable
compensation. In addition to the base salary, upon achievement of performance
objectives established by the Committee, officers could receive bonuses in
amounts ranging from 15% to 60% of their base salaries. The policy through 1998
also provided for award of stock options ranging in value from 25% to 75% of
base salary, based on an option valuation model, which were awarded as described
below. If performance objectives are achieved and officers receive the entire
amount of incentive compensation available to them, their compensation could be
at the highest percentiles of compensation for comparable positions. The
Committee believes that performance-based and stock-based compensation serve to
align the interests of the executive officers with the interests of the
Company's stockholders.
4
<PAGE>
Stock options to be received by officers pursuant to the executive
compensation policy described above are awarded under the 1993 Plan. Options
granted under the 1993 Plan become exercisable on the achievement of performance
objectives established by the Committee or 10 years from the date of grant. The
1993 Plan and the performance objectives are designed so that the options will
motivate the officers toward and reward them for achievement of the performance
objectives.
In November 1997, the Committee accelerated option grants to officers of
the Company, other than Dr. Lopez, by a one-time grant of options covering the
estimated number of shares which otherwise would be covered by options that the
Company would expect to award over a five year period under the executive
compensation policy described above. The options were granted with the
understanding that no additional options would be granted to the recipients
under the executive compensation policy for five years. At the time that the
options were granted, the Committee established a series of performance
objectives, which, if met, would cause the options to become exercisable earlier
than 10 years from the date of grant. It is expected that the performance
objectives will not be met until at least several years after the expected
awards normally would have been made. The Committee further provided that
options could not be exercised as to more than 20% cumulatively of the covered
shares each year from 1998 through 2002. A similar award was made to Dr. Lopez
in January 1998, but related only to options that might have been awarded in
1998.
Bonuses were paid to officers who were deemed to have met the performance
objectives for the first and second halves of 1999. No options were granted to
officers, other than Dr. Lopez, as a result of achievement of the performance
objectives for 1999 because of the grants awarded in November 1997 as described
above. In January 1999, additional options were granted to Mr. Costello
coincident with a salary adjustment.
The base salary paid to Dr. Lopez in 1999 was set by the Committee in
accordance with the Company's executive compensation policy at near the middle
of the range of total compensation paid to Chief Executive Officers of companies
that the Committee deemed to be comparable to the Company. Under the executive
compensation policy, Dr. Lopez received incentive bonuses of 55% (of a possible
maximum of 60%) of his base salary, and options on 11,008 shares of common
stock. In the second half of the year, the policy as it applies to Dr. Lopez was
amended to dispense with large grants that had been made at two to three year
intervals, and which were not covered by the semi-annual award policy described
above, and to grant him more options during each year than was provided for
under the executive compensation policy as in effect until that time.
Accordingly, in December 1999, Dr. Lopez was granted options on 88,992 shares of
common stock. The executive compensation policy sets the incentive bonuses and
the value of stock options to be awarded to Dr. Lopez at a higher percentage of
his base salary than that awarded to other officers. The Committee believes that
in view of the Chief Executive Officer's overall responsibility for the success
of the Company, it is appropriate that a larger portion of his compensation be
contingent on performance.
March 13, 2000
COMPENSATION COMMITTEE
As constituted during 1999
Jack W. Brown
Michael T. Kovalchik III, M.D.
Richard H. Sherman, M.D.
5
<PAGE>
SUMMARY OF CASH AND CERTAIN OTHER COMPENSATION
The following table shows the compensation earned for the past three years
by each of the Company's executive officers whose 1999 compensation exceeded
$100,000 (the "named executive officers").
<TABLE>
SUMMARY COMPENSATION TABLE
<CAPTION>
ANNUAL COMPENSATION LONG TERM
--------------------------- COMPENSATION
SECURITIES UNDERLYING ALL OTHER
NAME AND POSITION YEAR SALARY ($) BONUS(1) OPTIONS(#) COMPENSATION ($)
----------------- ------ ------------ -------- --------------------- ----------------
<S> <C> <C> <C> <C> <C>
George A. Lopez......................... 1999 $ 225,000 $ 123,750 100,000 $ 33,654(5)
Chairman of the Board, 1998 166,000 124,500 750,000
President and Chief Executive Officer 1997 166,000 124,500 750,000(2)
Francis J. O'Brien ..................... 1999 200,000 47,500 2,000
Secretary, Treasurer and 1998 150,000 65,000 2,000
Chief Financial Officer 1997 150,000 65,000 125,150(3)
1999 150,000 72,750 37,000
Richard A. Costello (4)................. 1998 100,000 115,870 2,000
Vice President of Sales 1997 102,185 55,750 69,111
1999 110,000 41,250 2,000
Evelyn L. Foss ......................... 1998 95,000 47,500 2,000
Vice President of Marketing 1997 117,657 47,500 105,949
</TABLE>
(1) Bonus amounts are included in the year earned rather than the year actually
paid; a portion is paid in the following year.
(2) Represents the cancellation and granting of 750,000 options.
(3) Represents the grant of 124,150 options and the cancellation and granting
of 1,000 options.
(4) Mr. Costello was elected Vice President of Sales on December 18, 1997.
(5) Dollar value of life insurance premiums paid by the Company, based on the
cost of term life insurance, plus the dollar value, on an actuarial basis,
of the net cash surrender value accruing to the Diana Lopez Insurance Trust
as owner of the life insurance policy on Dr. Lopez.
STOCK OPTION GRANTS
Options to purchase Common Stock of the Company were granted in 1999 to
employees under the 1993 Plan, which provides for the grant of options to
purchase up to 4,775,000 shares. The exercise price of options granted under the
1993 Plan is the fair market value of the Common Stock on the date of grant.
Options granted under the 1993 Plan expire eleven years from issuance and are
time-accelerated options which vest upon the earlier of the Company achieving
specific operating performance levels or ten years from the date of grant.
6
<PAGE>
<TABLE>
OPTION GRANTS IN LAST FISCAL YEAR
<CAPTION>
POTENTIAL REALIZABLE VALUE AT
ASSUMED ANNUAL RATES OF
STOCK PRICE APPRECIATION
INDIVIDUAL GRANTS FOR OPTION TERM
--------------------------------------------------------- --------------------------------
NUMBER OF % OF TOTAL EXERCISE
SECURITIES OPTIONS OR BASE
UNDERLYING GRANTED TO PRICE
OPTIONS EMPLOYEES PER SHARE EXPIRATION
NAME GRANTED (#) IN 1999 ($/SH) DATE 5%($)(1) 10%($)(1)
- ------------------------ --------------- ------------- ----------- ------------ -------------- --------------
<S> <C> <C> <C> <C> <C> <C>
George A. Lopez, M.D. 11,008 3% $ 16.00 9/2/10 $ 125,111 $ 326,386
88,992 27% 15.50 12/20/10 979,825 2,556,145
Francis J. O'Brien 1,000 * 21.44 1/2/10 15,228 39,726
1,000 * 17.38 7/1/10 12,342 32,198
Richard A. Costello 1,000 * 21.44 1/2/10 15,228 39,726
35,000 11% 16.34 1/12/10 406,338 1,060,044
1,000 * 17.38 7/1/10 12,342 32,198
Evelyn L. Foss 1,000 * 21.44 1/2/10 15,228 39,726
1,000 * 17.38 7/1/10 12,342 32,198
</TABLE>
- -------------
* Less than one percent
(1) The rates of stock appreciation reflected in the table are assumed solely
for the purpose of compliance with the rules of the Securities and Exchange
Commission relating to the disclosure of executive compensation. The
Company's Common Stock has at times appreciated at rates substantially
different than the assumed rates and at other times the value of the Common
Stock has declined. Neither the assumed appreciation rates nor the actual
changes in the share value since the dates of option grants are necessarily
indicative of any future value of the Common Stock. The actual realizable
value of the options may be substantially greater or less than that
reflected in the table depending on the actual changes in the share value
during the options' terms.
STOCK OPTION EXERCISES AND HOLDINGS
AGGREGATED OPTION EXERCISES IN 1999 AND YEAR-END OPTION VALUES
The following table contains information about stock options exercised
during 1999, and stock options held at December 31, 1999, by the named executive
officers of the Company.
<TABLE>
<CAPTION>
VALUE OF UNEXERCISED
SHARES NUMBER OF UNEXERCISED IN-THE-MONEY OPTIONS AT
ACQUIRED VALUE OPTIONS AT YEAR-END(#)(1) YEAR-END($)
NAME ON EXERCISE REALIZED EXERCISABLE/UNEXERCISABLE EXERCISABLE/UNEXERCISABLE
------------- ----------- -------- ------------------------- -------------------------
<S> <C> <C> <C> <C> <C> <C>
George A. Lopez, M.D. ....... --- --- 1,090,655 / 817,345 $ 4,545,090 / $ 2,152,035
Francis J. O'Brien .......... --- --- 46,509 / 127,150 351,162 / 534,647
Richard A. Costello ......... 25,625 $318,753 6,541 / 100,570 27,250 / 269,083
Evelyn L. Foss .............. --- --- 57,359 / 97,590 371,050 / 407,169
</TABLE>
7
<PAGE>
PERFORMANCE GRAPH
The following graph shows the total stockholder return on the Company's
Common Stock based on the market price of the Common Stock from January 1, 1994
to December 31, 1999 and the total returns of the Nasdaq Stock Market National
Market Tier Index and Common Stocks of a peer group selected by the Company for
the same period.
COMPARISON OF TOTAL RETURN FROM JANUARY 1, 1995 TO DECEMBER 31, 1999
AMONG ICU MEDICAL, INC., THE NASDAQ STOCK MARKET INDEX AND PEER GROUP
[Comparison of Total Return Graph Here]
<TABLE>
<CAPTION>
12/31/1994 12/31/1995 12/31/1996 12/31/1997 12/31/1998 12/31/1999
---------- ---------- ---------- ---------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C>
ICU Medical, Inc. 100.0 109.7 50.8 79.8 141.9 98.4
Nasdaq 100.0 141.3 173.9 213.1 300.2 545.7
Peer Group 100.0 190.9 138.5 79.2 65.3 92.8
</TABLE>
Assumes $100 invested on January 1, 1994 in the Company's Common Stock, the
Nasdaq Stock Market National Market Tier Index and the Peer Group.
The companies in the peer group selected by the Company are Gish
Biomedical, Inc., Isolyser Company, Inc., Merit Medical Systems, Inc., Utah
Medical Products, Inc. and Vital Signs, Inc. The basis for the selection of the
companies in the peer group is that, like the Company, they are all small to
mid-size producers of medical products. The peer group for the graph above has
been changed from the peer group for the 1998 performance graphs, by including
Isolyser Company, Inc., in place of Luther Medical Products, Inc. because there
has been no public market for Luther shares since its acquisition prior to
December 31, 1999.
DIRECTORS' COMPENSATION
During 1999, the Company paid directors who were not employees of the
Company an annual retainer of $10,000 plus $1,000 per day for attendance at
meetings of the Board and $500 if the meeting is conducted telephonically. Pay
for attendance at meetings of Committees of the Board is $750 per day, and $375
if the meeting is conducted telephonically. In addition, under the Directors'
Stock Award Plan, the Company automatically awards 1,000 shares of Common Stock
to each non-employee director on the date of each Annual Meeting.
8
<PAGE>
EMPLOYMENT AGREEMENTS
The Company has an employment agreement with each named executive officer,
which provides for an annual base salary and a bonus payable in cash and options
to acquire the Company's Common Stock under the 1993 Plan based on achievement
of specified performance goals. Unless earlier terminated, the employment
agreements expire on June 30, 2000, at which time they may be renewed for
successive six-month periods. The provisions for the bonus payable in options to
acquire the Company's Common Stock for all except Dr. Lopez was, in effect,
superceded by an award of stock options in November 1997 in place of options
that might have been awarded over the succeeding five years. Options vest only
upon the earliest of the Company achieving specific operating performance levels
or ten years from the date of grant.
CERTAIN TRANSACTIONS AND RELATIONSHIPS
The Company has, from time to time, made personal loans to Richard A.
Costello, who became Vice President of Sales of the Company on December 18,
1997. The largest amount outstanding during 1999 was $37,247. Outstanding
amounts bore interest at 4% to 6%, and the balance was repaid on February 17,
1999. In addition, in April, 1999 the Company made a $150,000 loan to Mr.
Costello to assist him in acquiring a home. It is secured by a second mortgage
which bears interest at 6% payable semi-annually and the loan is due April 28,
2004.
SELECTION OF AUDITORS
The Board of Directors of the Company has appointed Arthur Andersen LLP,
independent certified public accountants, as auditors of the Company for the
year ending December 31, 2000, and has further directed that management submit
the selection of auditors for ratification by the stockholders at the Annual
Meeting. Arthur Andersen LLP has audited the Company's financial statements for
the last ten years. Representatives of Arthur Andersen LLP are expected to be
present at the Annual Meeting and will have an opportunity to make a statement
if they so desire and respond to appropriate questions.
OTHER MATTERS
The Company knows of no other matters to be brought before the Annual
Meeting. If any other matters are properly presented for action, the persons
named in the accompanying proxy intend to vote on such matters in their
discretion.
ANNUAL REPORT
The Company's Annual Report for the year ended December 31, 1999, is being
mailed to all stockholders together with this Proxy Statement.
THE COMPANY WILL PROVIDE, WITHOUT CHARGE, A COPY OF ITS ANNUAL REPORT ON
FORM 10-K, INCLUDING FINANCIAL STATEMENTS AND RELATED SCHEDULES, FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION UPON REQUEST IN WRITING FROM ANY PERSON WHO
WAS A HOLDER OF RECORD, OR WHO REPRESENTS IN GOOD FAITH THAT HE OR SHE WAS A
BENEFICIAL OWNER, OF COMMON STOCK OF THE COMPANY ON MARCH 6, 2000. ANY SUCH
REQUEST SHALL BE ADDRESSED TO THE SECRETARY OF THE COMPANY AT 951 CALLE
AMANECER, SAN CLEMENTE, CA 92673.
9
<PAGE>
NOMINATION OF DIRECTORS AND
SUBMISSION OF STOCKHOLDER PROPOSALS
Any stockholder who intends to nominate persons for election as directors
at an annual meeting shall give timely written notice to the Secretary of the
Company setting forth (a) as to each nominee whom the stockholder proposes to
nominate for election or reelection as a director, (i) the name, age, business
address and residence address of the nominee, (ii) the principal occupation or
employment of the nominee, (iii) the class and number of shares of capital stock
of the corporation which are beneficially owned by the nominee and (iv) any
other information concerning the nominee that would be required under the rules
of the Securities and Exchange Commission in a proxy statement soliciting
proxies for the election of such nominee; and (b) as to the stockholder giving
the notice, (i) the name and record address of the stockholder and (ii) the
class and number of shares of capital stock of the Company which are
beneficially owned by the stockholder. Such notice shall include a signed
consent of each such nominee to serve as director of the Company, if elected.
The Company may require any proposed nominee to furnish such other information
as may reasonably be required by the Company to determine the eligibility for
such proposed nominee to serve as a director of the Company. Any stockholder who
intends to propose any business at a meeting shall give timely written notice to
the Secretary of the Company setting forth as to each matter the stockholder
proposes to bring before the meeting (i) a brief description of the business to
be brought before the meeting and the reasons for conducting the business at the
meeting, (ii) the name and record address of the stock holder giving the notice,
(iii) the class and number of shares of capital stock of the Company that are
beneficially owned by the stockholder, and by any other stockholders known by
the stockholder giving the notice to be supporting the proposal and (iv) any
material or financial interest of the stockholder in such business. Either of
the notices described above will be timely if it is delivered to or mailed and
received at the Company's executive offices not less than 50 days nor more than
75 days prior to the date of the annual meeting, unless the Company has given
less than 60 days notice or prior public disclosure of the date of the meeting,
in which case the notice must be received by the Company not less than 10 days
after notice of the meeting was mailed or public disclosure of the date of the
meeting was made. A proposal that a stockholder wants the Company to include in
the Proxy Statement for the 2001 Annual Meeting must be received by the Company
at its principal executive offices by November 20, 2000, to be included in the
Proxy Statement for that meeting, and all other conditions for such inclusion
must be satisfied.
COMPLIANCE WITH SECTION 16(A) OF THE SECURITIES EXCHANGE ACT OF 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
officers and directors and persons who own more than 10% of the Company's Common
Stock to file reports on prescribed forms regarding ownership of and
transactions in the Common Stock with the Securities and Exchange Commission and
to furnish copies of such forms to the Company. Based solely on a review of the
forms received by it, the Company believes that with respect to 1999 the
following Section 16(a) filing was not filed on a timely basis: Form 4 for
Robert S. Swinney, M.D. for one filing.
SOLICITATION OF PROXIES
The cost of this solicitation of proxies will be borne by the Company.
Solicitations will be made by mail, telephone or telegram and personally by
directors, officers and other employees of the Company, but such persons will
not receive compensation for such services over and above their regular
salaries. The Company will reimburse brokers, banks, custodians, nominees and
fiduciaries holding stock in their names or in the names of their nominees for
their reasonable charges and expenses in forwarding proxies and proxy material
to the beneficial owners of such stock.
BY ORDER OF THE BOARD OF DIRECTORS
/s/ Francis J. O'Brien
----------------------------------
Francis J. O'Brien, SECRETARY
10
<PAGE>
ICU MEDICAL, INC.
Annual Meeting of Stockholders
May 5, 2000
This Proxy is Solicited on Behalf of the Board of Directors
The undersigned hereby appoints George A. Lopez, M.D. and Francis J. O'Brien,
and each of them, proxies of the undersigned, each with full power to act
without the other and with power of substitution, to represent the undersigned
and vote as directed on the reverse all shares of stock of ICU Medical, Inc.
(the "Company") which the undersigned may be entitled to vote at the Annual
Meeting of Stockholders to be held on Friday, May 5, 2000, or any adjournments
thereof, and in their discretion upon such other business as may properly come
before the Annual Meeting or any adjournments thereof.
- --------------------------------------------------------------------------------
COMMENTS/ADDRESS CHANGE: PLEASE MARK COMMENT/ADDRESS BOX ON REVERSE SIDE
(Continued and to be signed on other side)
FOLD AND DETACH HERE
<PAGE>
- --------------------------------------------------------------------------------
Please mark
[X] your votes
as indicated
The shares represented by this Proxy will be voted as directed herein, but if
no directions are indicated, will be voted FOR the election of all nominees of
the Board of Directors, and FOR Proposal
Item 1-Election of directors WITHHELD
Jack W. Brown, and FOR FOR ALL
Richard H. Sherman, M.D. [_] [_]
Item 2-The proposal to ratify the selection FOR AGAINST ABSTAIN
of Arthur Andersen LLP as auditors [_] [_] [_]
for the Company.
PLEASE COMPLETE, DATE, SIGN AND MAIL THIS PROXY CARD PROMPTLY IN THE ENCLOSED
ENVELOPE.
Signature(s) ____________________________________________ Date __________, 2000
NOTE: Please sign exactly as your name appears hereon. When signing as attorney,
executor, administrator, trustee, or guardian, set forth your full title. When
shares are held in more than one name, both parties should sign.
FOLD AND DETACH HERE
